Piramal Critical Care announces US launch of Chlorpromazine Hydrochloride for Injection
The launch of Chlorpromazine Hydrochloride for Injection is the latest in a series of recent product launches from Piramal Critical Care
The launch of Chlorpromazine Hydrochloride for Injection is the latest in a series of recent product launches from Piramal Critical Care
The company is committed to unlocking new frontiers in neuroscience and developing Usnoflast for patients with ALS
The revenue from operations in Q3 FY25 is Rs. 8,358.6 crore, up 16% YoY
Olanzapine is indicated for the acute and maintenance treatment of schizophrenia and related psychotic disorders
According to IQVIATM sales data for the 12-month period ending November 2024, the Vitamin K1 Injectable Emulsion USP, 10 mg/mL market achieved annual sales of approximately $19.7 million
New Jersey-based manufacturing site to support innovative decentralized approach for improved patient experience
Mesalazine is used to treat inflammatory bowel disease
This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo
The company has paid an Interim Environmental Damage Compensation of Rs. 3.40 lakh to GPCB
The company ensures a reliable and strong portfolio at competitive prices without compromising on excellent quality
Subscribe To Our Newsletter & Stay Updated